

Endeavour Medtech Growth II Portfolio Impact Analysis

At Endeavour Vision, we invest in healthcare technologies that have the potential to change healthcare for the better. The Endeavour Medtech Growth II (EMG II) portfolio, established in 2020, focuses on innovative technologies across two key areas: medical devices and digital health.

We partner with growth-stage companies that are pioneering best-in-class solutions for some of the biggest challenges in healthcare. Our investment team supports our portfolio companies with strategic and operational expertise, working closely with them as they develop towards commercialisation — with the ultimate goal of bringing these groundbreaking technologies to more people.



14 companies
at end of 2023

total investment:

USD 375m

total of

**c. 3,000
employees**

How we think about Impact

We believe that delivering meaningful and sustainable impact is about improving care delivery and bettering the lives and well-being of patients and healthcare professionals. On top of that, we see impact as solving key challenges in the healthcare sector, such as the challenges of existing therapies, healthcare costs and workforce shortages.

We partner with companies that deliver impact across four key areas:

- **Saving and extending lives**
These technologies are providing breakthrough treatments, procedures, or efficiencies in diagnosis. Thus, they contribute to longer, healthier lives and reduce premature mortality from non-communicable diseases.
- **Improving quality of life**
Whether by treating chronic conditions, providing care that caters to patient preferences, or offering solutions to pain-points — these companies are contributing to happier and healthier lives for patients.
- **Promoting better work**
These companies are addressing challenges in the workplace. That might be via digital health solutions that improve working conditions for healthcare workers, or medical devices that enable people to manage their condition and resume normal activities such as going back to work.
- **Reducing costs**
These technologies reduce costs for patients and healthcare providers. For providers, this means optimising care delivery or mitigating financial losses. For patients, it means healthcare is more affordable — reducing health inequities and easing the financial burden of treatment.



EMG II portfolio and the SDGs

- Established in 2015, the UN SDGs are a collection of 17 global goals to support economic growth while addressing the major challenges faced by our planet.
- They aim to ignite global action to create a greener and fairer world by 2030.
- As healthcare struggles with ageing populations and an overstretched workforce, healthcare technologies have the potential to support the achievement of the SDGs.
- Thus, another way of measuring impact is to assess how companies can contribute towards the SDG targets.

SUSTAINABLE DEVELOPMENT GOALS



All EMG II portfolio companies contribute to:



SDG 3: Ensure healthy lives and promote well-being for all at all ages



SDG 8: Promote sustained, inclusive, and sustainable economic growth, full and productive employment and decent work for all




SDG 9: Build resilient infrastructure, promote inclusive and sustainable industrialisation, and foster innovation




Certain companies also contribute to:




SDG 4: Ensure inclusive and equitable quality education and promote lifelong learning opportunities for all











SDG 5: Achieve gender equality and empower all women and girls



SDG 12: Ensure sustainable consumption and production patterns



		Mission	Location	No. of employees	Impact areas	SDGs
Medical devices	CeQur	CeQur produce insulin delivery devices that make it easier for people living with diabetes to adhere to therapy and stay in control of their condition.	Horw, Switzerland	≤100	■ ■ ■ ■ ■	  
	Nalu	The Nalu™ Neurostimulation System is a battery-free, micro-implantable device for the treatment of chronic neuropathic pain.	Carlsbad, California, US	101-299	■ ■ ■ ■ ■	  
	Kestra	Kestra protects cardiac patients with diagnostic monitoring and therapeutic technologies that are intuitive, intelligent, and mobile.	Kirkland, near Seattle, Washington, US	101-299	■ ■ ■ ■ ■	  
	InBrace	InBrace's Smartwire® is a behind-the-teeth teeth straightener, which works on autopilot with no need for monthly tightenings.	Irvine, California, US	101-299	■	  
	Willow	Willow developed the first ever hands-free, wearable, cordless breast pump — revolutionising the way mothers breastfeed.	Mountainview, California, US	≤100	■ ■ ■ ■ ■	   
	Virtual Incision	Virtual Incision developed the MIRA, a miniaturised surgical robot to make minimally invasive procedures accessible to more patients.	Lincoln, Nebraska, US	≤100	■ ■ ■ ■ ■	  
	Relievant*	Relievant Medsystems provides a minimally invasive surgical solution to improve quality of life for patients living with vertebrogenic chronic low back pain.	Minneapolis, Minnesota, US	101-299	■ ■ ■ ■ ■	  
	Miach	Miach develop bio-engineered surgical implants for connective tissue restoration. Miach's BEAR® Implant has transformed the treatment of ACL tears.	Westborough, Massachusetts, US	≤100	■ ■ ■ ■ ■	  
Digital health	IntelyCare	IntelyCare's AI-based platform enables healthcare facilities to staff properly while providing nursing professionals with greater scheduling flexibility.	Boston, Massachusetts, US	≥300	■ ■ ■ ■ ■	   
	Lumeon	Lumeon optimises healthcare delivery by automating care orchestration via its cloud-based digital health platform, to deliver efficient, personalised care.	London, UK and Boston, Massachusetts, US	101-299	■ ■ ■ ■ ■	  
	Kenbi	Kenbi is a tech-enabled outpatient care provider in Germany offering a full range of professional care services at home.	Berlin, Germany	≥300	■ ■ ■ ■ ■	  
	HealthJoy	HealthJoy is a workplace healthcare navigation platform, which connects members with the right benefits at the right moment in their care journey.	Chicago, Illinois, US	≥300	■ ■ ■ ■ ■	  
Diagnostics /tools	Rapid Micro Biosystems**	Rapid Micro Biosystems provides a fully automated microbial quality control platform for biopharmaceutical manufacturing.	Boston, Massachusetts, US	101-299	■ ■ ■ ■ ■	   
	SOPHiA GENETICS***	SOPHiA GENETICS is the creator of a global data pooling and knowledge sharing platform that advances data-driven medicine.	Lausanne, Switzerland and Boston, Massachusetts, US	≥300	■ ■ ■ ■ ■	  

Key:

-  Saving and extending lives
-  Improving quality of life
-  Promoting better work
-  Reducing costs

*Acquired by Boston Scientific in 2023

**IPO in 2021 (NASDAQ: RPID)

***IPO in 2021 (NASDAQ: SOPH)